Overview

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Status:
Not yet recruiting
Trial end date:
2023-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of MK-0616, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia. The primary hypothesis is that at least one of the four doses of MK-0616 tested in this study is superior to placebo on percent change from baseline in LDL-C at Week 8.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.